SCHEMBL25409744

SCHEMBL25409744

O=C1Cc2ccccc2CN2CCCN12

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2A6 P11509 1/20 0.38
▸ HTR7 P34969 7/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RNASEH1 O60930 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTR1A P08908 3/20 0.35
▸ ACHE P22303 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ TLR9 Q9NR96 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25406983 0.78 TIPARP (0.34) KMT2ANOTUM
SCHEMBL31676161 0.76 TDP2 (0.40) KMT2ANOTUM
SCHEMBL28932616 0.72 MAOA (0.43) CYP1A2RXFP1HPGDACHENOTUM
SCHEMBL25407747 0.71 CYP1A2 (0.35) CYP1A2CYP2A6HTR7RXFP1KMT2A
SCHEMBL25408832 0.69 ANPEP (0.44) —
SCHEMBL25410229 0.69 ANPEP (0.44) —
SCHEMBL25436458 0.68 SPPL2A (0.40) NOTUMOPRM1OPRK1OPRL1
SCHEMBL25408472 0.67 KMT2A (0.44) CYP1A2KMT2ARNASEH1HPGDGAA
SCHEMBL31676159 0.67 CHRM2 (0.36) KMT2AOPRM1OPRK1OPRL1
SCHEMBL30617078 0.67 KMT2A (0.44) CYP1A2KMT2ARNASEH1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263416-A1 SPPL2a INHIBITORS INCYTE CORPORATION 2025-08-21 — — US disclosed
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 — — EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 — — EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 CYP1A2 3074/4885CYP2A6 3043/4885HTR7 3759/4885
US-20250263416-A1 SPPL2a INHIBITORS SPPL2A, SPPL2B, BACE1 CYP1A2 3126/4885CYP2A6 3131/4885HTR7 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback